A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK329 | GSK329 is a potent and selective inhibitor of cardiac-specific kinase TNNI3K (TNNI3 interacting kinase) with IC50 of 10 nM. Synonyms: GSK-329; GSK 329; N-(3,5-dichloro-4-{[6-(methylamino)pyrimidin-4-yl]oxy}phenyl)-N'-[3-(trifluoromethyl)phenyl]urea; N-[3,5-Dichloro-4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]-N-[3-(trifluoromethyl)phenyl]-urea. Grade: 98% by HPLC. CAS No. 1268490-12-5. Molecular formula: C19H14Cl2F3N5O2. Mole weight: 472.2. |  |
| GSK3326595 | GSK3326595, also called as EPZ015938, is an orally available and specific inhibitor of protein arginine methyltransferase 5 (PRMT5) that potently inhibits tumor growth in vitro and in vivo in animal models and has entered clinical trials for the treatment of solid tumors and non-Hodgkin's lymphoma. Synonyms: GSK-3326595; GSK 3326595; GSK3326595; EPZ015938; EPZ 015938; EPZ-015938; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide. CAS No. 1616392-22-3. Molecular formula: C24H32N6O3. Mole weight: 452.55. | |
| GSK3326595 | GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma[1][2][3][4][5]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: EPZ015938. CAS No. 1616392-22-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 1 g. Product ID: HY-101563. |  |
| GSK3326595 (Pemrametostat, EPZ015938) | Pemrametostat (GSK3326595, EPZ015938) is an orally active, potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) and potently inhibits tumor growth in vitro and in vivo in animal models. Group: Inhibitors. Alternative Names: EPZ015938. CAS No. 1616392-22-3. Pack Sizes: 5mg. Product ID: S8664. Formula: C24H32N6O3. Smiles: CC(=O)N1CCC(CC1)NC2=NC=NC(=C2)C(=O)NCC(CN3CCC4=CC=CC=C4C3)O. Storage Conditions: 2 years -80 in solvent. |  United States; Europe |
| GSK3368715 | GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: EPZ019997. CAS No. 1629013-22-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-128717. | |
| GSK3368715 3HCl | GSK3368715 is a potent reversible inhibitor of type I protein arginine methyltransferases (PRMT) with antitumor activity. Synonyms: EPZ019997 3HCl. CAS No. 2227587-26-8. Molecular formula: C20H41Cl3N4O2. Mole weight: 475.92. | |
| GSK3368715 dihydrochloride | GSK3368715 dihydrochloride is a reversible, orally active and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor with IC50s of 3.1, 48, 1148, 5.7 and 1.7 nM for PRMT1, PRMT3, PRMT4, PRMT6 and PRMT8, respectively. It can change the methylation states of arginine, alter the use of exons, and has strong anticancer activity. Synonyms: EPZ019997 dihydrochloride; N-({3-[4,4-Bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl}methyl)-N,N'-dimethyl-1,2-ethanediamine dihydrochloride; 1,2-Ethanediamine, N1-[[3-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl]methyl]-N1,N2-dimethyl-, hydrochloride (1:2). Grade: ≥95%. CAS No. 1628925-77-8. Molecular formula: C20H40Cl2N4O2. Mole weight: 439.46. | |
| GSK3368715 dihydrochloride | GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: EPZ019997 dihydrochloride. CAS No. 1628925-77-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-128717A. | |
| GSK343 | GSK343, a chemical probe, is a highly potent and selective EZH2 inhibitor with an IC50 of 4 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1346704-33-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13500. | |
| GSK343 | GSK343 is a potent, selective inhibitor of EZH2 with cellular activity. GSK343 inhibits EZH2 with an IC50 of 4nM and is over 1000-fold selective for other HMTs except EZH1 (60-fold selectivity). GSK343 inhibits H3K27 methylation in HCC1806 cells with an IC50 of <200nM as measured by immunofluorescence. GSK343 exhibited limited effects on the growth of EOC cells in conventional two-dimensional (2D) culture. In contrast, GSK343 significantly suppressed the growth of EOC cells cultured in 3D matrigel extracellular matrix (ECM), which more closely mimics the tumor microenvironment in vivo. Notably, GSK343 induces apoptosis of EOC cells in 3D but not 2D culture. In addition, GSK343 significantly inhibited the invasion of EOC cells. Synonyms: GSK343; GSK-343; GSK 343. CAS No. 1346704-33-3. Molecular formula: C31H39N7O2. Mole weight: 541.7. | |
| GSK-345931A | GSK-345931A is an EP(1) receptor antagonist. It is efficient in preclinical models of inflammatory pain. Uses: Inflammatory pain. Synonyms: 869499-38-7(sodium); 6-(5'-chloro-2'-(2-methylpropoxy)(1,1'-biphenyl)-2-yl)- 2-Pyridinecarboxylic acid. Grade: 98%. CAS No. 869534-13-4. Molecular formula: C22H20ClNO3. Mole weight: 381.86. | |
| GSK-345931A sodium | GSK-345931A is an EP(1) receptor antagonist. It is efficient in preclinical models of inflammatory pain. Uses: Inflammatory pain. Synonyms: GSK-345931A sodium; GSK 345931A sodium; GSK345931A sodium; 869534-13-4(Free); 6-(5'-chloro-2'-(2-methylpropoxy)(1,1'-biphenyl)-2-yl)- 2-Pyridinecarboxylic acid sodium salt. Grade: 98%. CAS No. 869499-38-7. Molecular formula: C22H19ClNNaO3. Mole weight: 403.83. | |
| GSK-3484862 | GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1). GSK-3484862 induces DNA hypomethylation to against cancer. GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2170136-65-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg; 1 g. Product ID: HY-135146. | |
| GSK-356278 | GSK-356278 is a selective Type 4 cyclic nucleotide phosphodiesterase inhibitor. It shows anxiolytic and cognition-enhancing effects and it has the ability to elevate cAMP in various cell types of the central nervous system. No development was reported for phase-I development in Major depressive disorder and Huntington's-disease. Uses: Huntington's disease; major depressive disorder. Synonyms: GSK-356278; GSK356278; GSK 356278; 5-(5-((2,4-dimethyl-5-thiazolyl)methyl)-1,3,4-oxadiazol-2-yl)-1-ethyl-n-(tetrahydro-2H-pyran-4-yl)-1H-Pyrazolo(3,4-b)pyridin-4-amine. Grade: 98%. CAS No. 720704-34-7. Molecular formula: C21H25N7O2S. Mole weight: 439.54. | |
| GSK360A | GSK360A orally active HIF-PHD inhibitor. GSK360A exerts systemic and local effects by stabilizing HIF-1α signaling and improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction. These findings suggest that GSK360A may be suitable for the treatment of post-MI remodeling and heart failure. Group: Biochemicals. Alternative Names: N- [ [1- (2-Cyclopropylethyl) -6-fluoro-1, 2-dihydro-4-hydroxy-2-oxo-3-quinolinyl] carbonyl] glycine; N- [ [1- (2-Cyclopropylethyl) -6-fluoro-4-hydroxy-2-oxo-1, 2-dihydro-3-quinolinyl] carbonyl] glycine. Grades: Highly Purified. CAS No. 931399-19-8. Pack Sizes: 5mg. US Biological Life Sciences. |  Worldwide |
| GSK360A | GSK360A is a potent and orally active HIF-PHD inhibitor with IC50 values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) [1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 931399-19-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-123422. | |
| GSK 366 | GSK 366 is a type II kynurenine-3-monooxygenase (KMO) inhibitor with IC50 values of 2.3 nM and 0.7 nM for human KMO and P. fluorescens-KMO (Pf-KMO). GSK 366 binds to KMOs substrate site, prevents productive NADPH association, substrate binding, and FAD hydroperoxy species formation. GSK 366 does not stimulate hydrogen peroxide (H2O2) production and reduces H2O2 levels. GSK 366 can be used for the researches of inflammation and neurological disease, such as acute pancreatitis multiple organ dysfunction syndrome and Alzheimers disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1953157-39-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-119171. | |
| GSK3685032 | GSK3685032 is a non-time-dependent, non-covalent, first-in-class reversible and selective inhibitor of DNMT1, with IC50 of 0.036 μM. GSK3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition. Synonyms: GSK-3685032; GSK 3685032. CAS No. 2170137-61-6. Molecular formula: C22H24N6OS. Mole weight: 420.53. | |
| GSK-3685032 | GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2170137-61-6. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139664. | |
| GSK369796 Dihydrochloride | SK369796, also known as N-tert-butylisoquine, shows antimalerial activity with IC50 values of 11.2 nM for 3D7 strain, 12.6 nM for HB3 strain, 17.6 nM for K1 strain. GSK369796 was rationally designed based on chemical, toxicological, pharmacokinetic, and pharmacodynamic considerations and was selected based on excellent activity against Plasmodium falciparum in vitro and rodent malaria parasites in vivo. Synonyms: 2-[(tert-Butylamino)methyl]-5-[(7-chloroquinolin-4-yl)amino]phenol Dihydrochloride; GSK369796 Dihydrochloride; GSK 369796; GSK-369796; GSK369796; N-tert-Butyl isoquine. CAS No. 1010411-21-8. Molecular formula: C20H24Cl3N3O. Mole weight: 428.78. | |
| GSK376501A | GSK376501A is a bio-active chemical compound used for the treatment of type 2 diabetes and hypercholesterolemia. It was developed by GlaxoSmithKline and was once in clinic phase 1, but now it has been terminated. Uses: Gsk376501a is used for the treatment of type 2 diabetes and hypercholesterolemia. Synonyms: GSK-376501A; GSK376501; GSK-376501; 1-[[3,5-bis(2-methoxyethoxy)phenyl]methyl]-3-(4-tert-butylphenyl)indole-2-carboxylic acid; 1H-Indole-2-carboxylic acid, 1-((3,5-bis(2-methoxyethoxy)phenyl)methyl)-3-(4-(1,1-dimethylethyl)phenyl)-. Grade: >98 %. CAS No. 1010412-80-2. Molecular formula: C32H37NO6. Mole weight: 531.64. | |
| GSK3787 | GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist with pIC50 of 6.6. Uses: Scientific research. Category: Signaling pathways. CAS No. 188591-46-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15577. | |
| GSK 3787 | GSK 3787. Group: Biochemicals. Grades: Purified. CAS No. 188591-46-0. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK-3787 | GSK-3787 is a potent and selective ligand for PPARdelta with good pharmacokinetic properties. Synonyms: GSK-3787; GSK3787; GSK 3787. CAS No. 188591-46-0. Molecular formula: C15H12ClF3N2O3S. Mole weight: 392.78059. | |
| GSK3987 | GSK3987 is a pan LXRα/β agonist. Synonyms: GSK-3987; GSK 3987; 1-Benzyl-3-[(4-methoxyphenyl)amino]-4-phenyl-1H-pyrrole-2,5-dione. Grade: >98%. CAS No. 264206-85-1. Molecular formula: C24H20N2O3. Mole weight: 384.43. | |
| GSK-3β Antibody [B6C8] | GSK3 beta,GSK3 beta (phospho S9),GSK-3β. Group: Antibodies. Pack Sizes: 20ul. Product ID: F0142. Storage Conditions: -20°C (avoid freeze-thaw cycles), 2 years. | United States; Europe |
| GSK3β-IN-2 | GSK3β-IN-2 (Compound S01) is the inhibitor for GSK3β with an IC50 of 0.35 nM. GSK3β-IN-2 activates Wnt/β-catenin signaling pathway, promotes neurogenesis and neurite growth. GSK3β-IN-2 inhibits Aβ-induced tau hyperphosphorylation at Ser396, reduces the formation of neurofibrillary tangles. GSK3β-IN-2 ameliorates Alzheimer's Disease in zebrafish model[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3068378-38-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-172171. | |
| GSK-3β inhibitor 1 | GSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor (IC50 = 4.9 nM) with high antidiabetic efficacy. Synonyms: 3-[(Z)-(2-Pyridinyl)methylene]indoline-2-one; (3Z)-3-(2-pyridinylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(pyridin-2-ylmethylene)-1,3-dihydro-2H-indol-2-one; 2H-Indol-2-one, 1,3-dihydro-3-(2-pyridinylmethylene)-, (3Z)-. Grade: ≥95%. CAS No. 187325-53-7. Molecular formula: C14H10N2O. Mole weight: 222.24. | |
| GSK-3β inhibitor 1 | GSK-3β inhibitor 1 (compound 3a) inhibits GSK-3β with an IC50 of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 187325-53-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-126144. | |
| GSK-3β inhibitor 12 | GSK-3β inhibitor 12 is an inhibitor of GSK-3β, an enzyme playing an essential function in T cell differentiation and proliferation. Synonyms: GSK-3beta inhibitor 12; 2-(1H-Indol-3-yl)-N-(5-methylthiazol-2-yl)acetamide. CAS No. 784170-07-6. Molecular formula: C14H13N3OS. Mole weight: 271.34. | |
| GSK-3β inhibitor 2 | GSK-3β inhibitor 2 is a potent, selective and orally active GSK-3β inhibitor (IC50 = 1.1 nM) that can cross the blood-brain barrier and has the potential to treat Alzheimer's disease. Synonyms: 2-(2-(Cyclopropanecarboxamido)pyridin-4-yl)-4-methoxythiazole-5-carboxamide; 2-{2-[(Cyclopropylcarbonyl)amino]-4-pyridinyl}-4-methoxy-1,3-thiazole-5-carboxamide; 5-Thiazolecarboxamide, 2-[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]-4-methoxy-. Grade: ≥98%. CAS No. 1702428-31-6. Molecular formula: C14H14N4O3S. Mole weight: 318.35. | |
| GSK-3β inhibitor 2 | GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active GSK-3β inhibitor with an IC50 of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1702428-31-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-130795. | |
| GSK-3β inhibitor 22 | GSK-3β inhibitor 22 (compound 20o) is a GSK-3β inhibitor with an IC50 of 3.1 nM. GSK-3β inhibitor 22 has the potential of the study of Alzheimer's disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1005199-84-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg. Product ID: HY-164907. | |
| GSK-3β inhibitor 3 | GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1448990-73-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-141480. | |
| GSK-3β inhibitor 3 | GSK-3β inhibitor 3, a potent, selective, irreversible and covalent glycogen synthase kinase 3β (GSK-3β) inhibitor (IC50 = 6.6 μM), is used in the study of acute promyelocytic leukemia. Synonyms: 5-Acryloyl-2-(4-fluorophenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4(5H)-one; 5-Acryloyl-2-(4-fluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 1,5-Benzothiazepin-4(5H)-one, 2-(4-fluorophenyl)-2,3-dihydro-5-(1-oxo-2-propen-1-yl)-; 5-Acryloyl-2,3-dihydro-2-(4-fluorophenyl)-1,5-benzothiazepin-4(5H)-one. Grade: ≥95%. CAS No. 1448990-73-5. Molecular formula: C18H14FNO2S. Mole weight: 327.37. | |
| GSK3β Inhibitor II | GSK3β Inhibitor II is a potent and selective inhibitor of glycogen synthase kinase-3β (GSK3β) with an IC50 value of 390 nM. Synonyms: ?Glycogen Synthase Kinase 3β?? Inhibitor II; Tip-oxadiazole; 4-[5-[[(3-iodophenyl)methyl]thio]-1,3,4-oxadiazol-2-yl]-pyridine; 2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole. Grade: ≥95%. CAS No. 478482-75-6. Molecular formula: C14H10IN3OS. Mole weight: 395.2. | |
| GSK3β Inhibitor XI | GSK3β inhibitor XI is a cell-permeable, potent and ATP-competitive inhibitor of glycogen synthase kinase 3β (GSK3β; Ki = 25 nM) which is selective for GSK3β over a panel of 79 commonly studied protein kinases. Synonyms: 3-[1-(3-hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-4-(2-pyrazinyl)-1H-pyrrole-2,5-dione. Grade: ≥98%. CAS No. 626604-39-5. Molecular formula: C18H15N5O3. Mole weight: 349.3. | |
| GSK3β Inhibitor XVIII | GSK3β inhibitor XVIII is a cell-permeable, potent and selective inhibitor of glycogen synthase kinase 3β (GSK3β; IC50 = 64 nM). Synonyms: [2-chloro-4-[[4-(2-thienyl)-2-pyrimidinyl]amino]phenyl](4-methyl-1-piperazinyl)-methanone. Grade: ≥98%. CAS No. 1139875-74-3. Molecular formula: C20H20ClN5OS. Mole weight: 413.9. | |
| GSK-3beta Inhibitor XXIV (2-Methyl-5- (3-[4- (methylsulfinyl) phenyl) -1-benzofuran-5-yl) -1, 3, 4-oxadiazole, Racemic) | An orally bioavailable and blood-brain-barrier permeable oxadiazolo-benzofuranyl phenyl sulfoxide compound that acts as a potent, reversible and ATP-competitive inhibitor of GSK-3b (IC50=35nM, 34 and 140nM for racemic, (S)-9b eutomer and (R)-9b distomer). The (S)-9b eutomer displays excellent selectivity (IC50 > 10uM) over Cdk1/2/5, Chk1, p38a, JNK1, MEKK1, IKKb, PKCth, CK1d, EGFR, ErbB2, Src, Lck, IR, Tie2, c-Kit, c-Met, VEGFR2, FGFR3 and PDGFRa/b, and lowers tau phosphorylation at GSK-3b-Thr205 in a CWS (cold water stress) mouse model (3mg/kg, p.o.). Group: Biochemicals. Grades: Highly Purified. CAS No. 1005201-24-0. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| GSK-3beta Inhibitor XXV (GSK-3beta, N-(3-Chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine, 5-(4-Nitrophenyl)-N-(3-chloro-4-methyl)phenyl-1,3,4-oxadiazol-2-amine) | A blood brain barrier permeable oxadiazole compound that acts as a potent, reversible and ATP-competitive inhibitor of GSK-3b activity (IC50=17.1nM) with excellent selectivity over Cdk2 (22% inhibition at 10uM). Shown to elevate liver glycogen levels by ~3.5- and ~4.3-fold in C57BL/6N mice when dosed at 5 and 15mg/kg (i.p.) amounts. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. Molecular Formula: C??H??ClN?O?. US Biological Life Sciences. | Worldwide |
| GSK-3 beta Inhibitor XXVII (3-Amino-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide, HCl) | A cell-permeable pyridinyl pyrazinecarboxamide compound that acts as a highly potent, reversible, and ATP-competitive inhibitor of GSK-3b (Ki=4.9nM) with ~110-fold greater selectivity over Cdk2 (Ki=540nM). Shows only a trivial effect on the activities of 26-related kinases at much higher doses. Blocks GSK-3b-mediated phosphorylation of Ser396 in stably transfected 3T3 fibroblasts expressing four-repeat tau protein (IC50=76nM). Readily crosses blood-brain barrier and exhibits desirable bioavailability and aqueous solubility. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| GSK-3beta Inhibitor XXVII, CESI (2-(3-chloro-4-hydroxyphenyl)-8-(1,1-dioxidoisothiazolidin-2-yl)-3-hydroxy-6-methyl-4H-chromen-4-one) | A cell-permeable, 3-hydroxychromone derived compound that acts as a selective and reversible inhibitor of GSK-3beta (IC50 < 100nM). Shown to increase phosphorylation at Ser9. Does not show any inhibitory effect on a panel of 15 other protein kinases, including AMPK and Akt. By blocking GSK-3beta activity, it acts as a positive regulator of b-catenin signaling. Does not affect the viability or the growth rate of 3T3-L1 preadipocytes, however, it significantly reduces their differentiation into adipocytes ( 50 to 100nM). Exerts anti-adipogenic activity by down-regulating C/EBPa and PPARg. Shown to reduce adipocyte size and diminish weight gain in diet-induced obese mice without affecting their daily food intake. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. Molecular Formula: C??H??ClNO?S, Primary Target: GSK3b. US Biological Life Sciences. | Worldwide |
| GSK3β-peptide | GSK3β-peptide is a substrate mimetic peptide of glycogen synthase kinase 3-β (GSK3-β) that can bind to the active site of GSK3-β and mimic the behavior of a real substrate. GSK3β-peptide can be used to develop substrate mimetic inhibitors of Akt as potential anticancer drugs[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 496856-73-6. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P10605. | |
| GSK-3b Inhibitor XI | GSK-3b Inhibitor XI (Compound 33) is a potent and selective GSK3β inhibitor, with a Ki value of 25 nM. GSK-3b Inhibitor XI increases glycogen synthase (GS) activity. GSK-3b Inhibitor XI can be used for research on type 2 diabetes and Alzheimers disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 626604-39-5. Pack Sizes: 1 mg. Product ID: HY-112388. | |
| GSK-3/CDK5/CDK2-IN-1 | GSK-3/CDK5/CDK2-IN-1, an inhibitor of CDK5, CDK2 and GSK-3, can be used in the study of cancer and neurodegenerative diseases. (Extracted from patent WO2002010141A1, example 9a). Synonyms: 2-Naphthaleneacetamide, N-[1-[cis-3-(acetylamino)cyclobutyl]-1H-imidazol-4-yl]-; N-(1-((1s,3s)-3-acetamidocyclobutyl)-1H-imidazol-4-yl)-2-(naphthalen-2-yl)acetamide; N-[1-(cis-3-Acetamidocyclobutyl)-1H-imidazol-4-yl]-2-(2-naphthyl)acetamide. Grade: ≥98%. CAS No. 395074-72-3. Molecular formula: C21H22N4O2. Mole weight: 362.42. | |
| GSK3-IN-3 | GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a GSK-3 inhibitor with an IC50 value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 331963-27-0. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153089. | |
| GSK-3 inhibitor 1 | GSK-3 inhibitor 1 is a potent GSK-3 inhibitor. Grade: >98%. CAS No. 603272-51-1. Molecular formula: C22H17ClFN5O2. Mole weight: 437.85. | |
| GSK-3 Inhibitor, AR-A014418, (N-[(4-Methoxyphenyl)methyl]-N-(5-nitro-2-thiazolyl)urea) | Cell-permeable. A selective glycogen synthase kinase 3 (GSK-3) inhibitor (IC50 = 104nm). Inhibition is competitive with respect to ATP (Ki = 38nm). Exhibits specificity for GSK-3 over cdk2 and cdk5 (IC50 values are > 100 =um) and over 26 other kinases. Inhibits b-amyloid-mediated neurodegeneration in hippocampal slices. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 2mg. Molecular Formula: C??H??N?O?S. US Biological Life Sciences. | Worldwide |
| GSK 3 Inhibitor IX | GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively. Uses: Scientific research. Category: Signaling pathways. Alternative Names: 6-Bromoindirubin-3'-oxime; BIO; MLS 2052. CAS No. 667463-62-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10580. | |
| GSK-3 Inhibitor IX ((2Z,3E)-6-Bromoindirubin-3-oxime) | A cell-permeable bis-indolo (indirubin) compound that acts as a highly potent, selective, reversible, and ATP-competitive inhibitor of GSK-3a/b (IC50=5nM). Its specificity has been tested against various Cdk's (IC50=83, 300, 320, and 10,000nM for Cdk5/p25, Cdk2/A, Cdk1/B, and Cdk4/D1, respectively) as well as many other commonly studied kinases (IC50≥10uM), including MAP kinases, PKA, PKC isoforms, PKG, CK, and IRTK. Inhibition of GSK by BIO has been shown to result in the activation of Wnt-signaling pathway and sustained pluripotency in human and murine ESCs (embryonic stem cells). Reported to maintain self-renewal in human and mouse embryonic stem cells. Also induces the differentiation of neonatal cardiomyocytes. Group: Biochemicals. Grades: Highly Purified. CAS No. 667463-62-9. Pack Sizes: 1mg, 10mg. US Biological Life Sciences. | Worldwide |
| GSK-3 Inhibitor XIII | An inhibitor of GSK-3. Synonyms: (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine. Grade: >98%. CAS No. 404828-14-4. Molecular formula: C18H15N5. Mole weight: 301.3. | |
| GSK3 Inhibitor XIII | GSK3 Inhibitor XIII is a potent and ATP-competitive inhibitor of glycogen synthase kinase 3 (GSK3). Synonyms: Glycogen Synthase Kinase 3 Inhibitor XIII; 5,6,7,8-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-4-quinazolinamine. Grade: ≥98%. CAS No. 404828-08-6. Molecular formula: C18H19N5. Mole weight: 305.4. | |
| GSK3 Inhibitor XV | GSK3 inhibitor XV is a racemic mixture of (R)-GSK3 inhibitor XV and (S)-GSK3 inhibitor XV. (R)-GSK3 inhibitor XV inhibits glycogen synthase kinase (GSK) 3α and β with IC50 values of 0.35 and 0.55 nM respectively. (S)-GSK3 inhibitor XV is less potent than the (R)-GSK3 inhibitor XV. Synonyms: [11-bromo-9-hydroxypyrido[2,3-a]pyrrolo[3,4-c]carbazole-5,7(1H,6H)-dionato-κN1,κN12]carbonyl[(1,2,3,4,5-η)-1-(methoxycarbonyl)-2,4-cyclopentadien-1-yl]-ruthenium. Grade: ≥98%. CAS No. 936112-69-5. Molecular formula: C25H14BrN3O6Ru. Mole weight: 633.40. | |
| GSK4027 | GSK4027 is a potent and selective inhibitor of p300/CBP-associated factor (PCAF)/general control nonderepressible 5 (GCN5) bromodomain (Ki = 1.4 nM; IC50 = 60 nM in a chromatin engagement assay). Synonyms: 4-bromo-2-methyl-5-[[(3R,5R)-1-methyl-5-phenyl-3-piperidinyl]amino]-3(2H)-pyridazinone. Grade: ≥95%. CAS No. 2079896-25-4. Molecular formula: C17H21BrN4O. Mole weight: 377.3. | |
| GSK 4027 | GSK 4027 is a chemical probe for the PCAF/GCN5 bromodomain with an pIC50 of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. Uses: Scientific research. Category: Signaling pathways. CAS No. 2079896-25-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101027. | |
| GSK4028 | GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC50 of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. Uses: Scientific research. Category: Signaling pathways. CAS No. 2079886-19-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101027A. | |
| GSK4112 | GSK 4112, a kind of synthetic agonist of REV-ERBα, could suppress the expression of sorts of genes involved in gluconeogenesis. IC50: 0.4 μM (EC50). Uses: Gsk 4112 is a kind of synthetic agonist of rev-erbα and could suppress the expression of sorts of genes involved in gluconeogenesis. Synonyms: GSK4112; GSK 4112; GSK-4112. SR6452; CHEMBL1961795; 1216744-19-2; MLS006010708; GTPL2903. Grade: 95%. CAS No. 1216744-19-2. Molecular formula: C18H21ClN2O4S. Mole weight: 396.89. | |
| GSK4112 | GSK4112 (SR6452) is a Rev-erbα agonist with an EC50 value of 0.4 μM. GSK4112 can be used as a chemical tool to probe the function of Rev-erbα in transcriptional repression, regulation of circadian biology, and metabolic pathways[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: SR6452. CAS No. 1216744-19-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-14414. | |
| GSK 4112 | GSK 4112. Group: Biochemicals. Grades: Purified. CAS No. 1216744-19-2. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK429286A | GSK429286A is a selective inhibitor of ROCK1 with an IC50 value of 14 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 864082-47-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-11000. | |
| GSK429286A | GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively. Uses: Reprogramming, self-renewal. Synonyms: GSK 429286A; GSK-429286A. Grade: 0.98. CAS No. 864082-47-3. Molecular formula: C21H16F4N4O2. Mole weight: 432.37. | |
| GSK4418959 | GSK4418959 (IDE275) is a selective, reversible and orally active WRN helicase inhibitor. GSK4418959 shows >10,000-fold selectivity over other helicases. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer, such as colorectal cancer (CRC) and endometrial cancer (EC)[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: IDE275. CAS No. 3064599-36-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-169422. | |
| GSK461364 | GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a Ki value of 2.2 nM. Uses: Scientific research. Category: Signaling pathways. Alternative Names: GSK461364A. CAS No. 929095-18-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-50877. | |
| GSK-461364 | GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Synonyms: GSK461364; GSK 461364; GSK-461364; GSK461364A; GSK 461364A; GSK-461364A. 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide. CAS No. 929095-18-1. Molecular formula: C27H28F3N5O2S. Mole weight: 543.609. | |
| GSK 461364 analogue I | GSK 461364 analogue I is a potent polo-like kinase (PLK) inhibitor with selectivity for PLK1 (IC50: 2 nM) over PLK3 (IC50: 630 nM). Synonyms: GSK 461364 analogue I; GSK461364 analogue I; GSK-461364 analogue I; GSK579289A; GSK 579289A; GSK-579289A. Compound 25 [PMID 19237286]; 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(1-methylpiperidin-4-yl)oxybenzimidazol-1-yl]thiophene-2-carboxamide. Grade: 99%. CAS No. 929095-23-8. Molecular formula: C26H27ClN4O3S. Mole weight: 511.04. | |
| GSK 461364 analogue II | GSK 461364 analogue II is a potent polo-like kinase (PLK) inhibitor with selectivity for PLK1 (IC50: 2 nM) over PLK3 (IC50: 270 nM). Synonyms: GSK 461364 analogue II; GSK461364 analogue II; GSK-461364 analogue II; 5-[6-(1-methylpiperidin-4-yl)oxybenzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide. Grade: 99%. CAS No. 929095-22-7. Molecular formula: C27H27F3N4O3S. Mole weight: 544.59. | |
| GSK466317A | GSK466317A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor. Synonyms: GSK466317A; GSK-466317A; GSK 466317A. N-(7-chloro-1H-indazol-5-yl)-6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyridine-5-carboxamide. Grade: 98%. CAS No. 864082-48-4. Molecular formula: C21H16ClF3N4O2. Mole weight: 448.83. | |
| GSK467 | GSK467 is a cell penetrant and selective inhibitor of KDM5B (JARID1B/PLU1) with Ki of 10 nM. Synonyms: GSK-467; GSK 467. CAS No. 1628332-52-4. Molecular formula: C17H13N5O2. Mole weight: 319.32. | |
| GSK467 | GSK467 is a cell penetrant and selective KDM5B (JARID1B or PLU1) inhibitor with a Ki of 10 nM and an IC50 of 26 nM. GSK467 shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1628332-52-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-116761. | |
| GSK 4716 | GSK 4716 is a selective agonist of estrogen-related receptors ERRβ and ERRγ displaying selectivity over ERRα and the classical estrogen receptors. Activation of GSK 4716 regulates mitochondrial activity in skeletal muscle during exercise. Synonyms: GSK4716; GSK 4716; GSK-4716; 4-Hydroxy-2-[(1E)-[4-(1-methylethyl)phenyl]methylene]hydrazide. Grade: ≥99% by HPLC. CAS No. 101574-65-6. Molecular formula: C17H18N2O2. Mole weight: 282.34. | |
Our database is helping our users find suppliers everyday.
